User login
Canakinumab, an interleukin-1–beta blocker, reduced the risk of a gout attack by 52% when administered every 3 months, according to a secondary exploratory analysis of data from the multicenter, randomized, double-blind, placebo-controlled CANTOS trial (NCT01327846). The results of this analysis were published Sept. 17 in the Annals of Internal Medicine (doi: 10.7326/M18-1167).
We covered this story before it was published in the journal. Find our conference coverage at the links below.
Canakinumab, an interleukin-1–beta blocker, reduced the risk of a gout attack by 52% when administered every 3 months, according to a secondary exploratory analysis of data from the multicenter, randomized, double-blind, placebo-controlled CANTOS trial (NCT01327846). The results of this analysis were published Sept. 17 in the Annals of Internal Medicine (doi: 10.7326/M18-1167).
We covered this story before it was published in the journal. Find our conference coverage at the links below.
Canakinumab, an interleukin-1–beta blocker, reduced the risk of a gout attack by 52% when administered every 3 months, according to a secondary exploratory analysis of data from the multicenter, randomized, double-blind, placebo-controlled CANTOS trial (NCT01327846). The results of this analysis were published Sept. 17 in the Annals of Internal Medicine (doi: 10.7326/M18-1167).
We covered this story before it was published in the journal. Find our conference coverage at the links below.
FROM THE ANNALS OF INTERNAL MEDICINE